More about

Schizophrenia

News
January 07, 2022
1 min read
Save

FDA approves supplemental new drug application for Rexulti in pediatric patients

The FDA has approved the supplemental new drug application for Rexulti for treating schizophrenia in patients aged 13 to 17 years, Otsuka and Lundbeck announced.

News
January 06, 2022
2 min read
Save

Polygenic risk scores may be useful in finding bipolar disorder link in adults, offspring

Using polygenic risk scores to determine likelihood of parental bipolar disorder passing to offspring is promising but unproven, according to a community-based case-control longitudinal study published in JAMA Psychiatry.

News
January 04, 2022
2 min read
Save

Symptoms of patients with personality disorders worsened during COVID-19 lockdown

Patients with personality disorders experienced worsened symptoms, some of which have not improved, during the COVID-19 pandemic, according to an observational retrospective study published in Psychiatry Research.

News
January 03, 2022
1 min read
Save

Top psych stories of 2021: Omega-3 slows stress-linked aging, CBD aids health care workers

Healio Psychiatry’s five most-viewed stories of the year highlight a study on omega-3 supplementation and stress-related accelerated aging, research into the benefits of cannabidiol for frontline health care workers and data on the link between OCD and increased risk for dementia/Alzheimer’s disease.

News
December 16, 2021
2 min read
Save

Women, those with prior attempts more likely to take their own lives in schizophrenia

Individuals with schizophrenia who died by suicide were more likely to be older, have previous suicide attempts and be women, according to data published in Psychiatry Research.

News
December 14, 2021
1 min read
Save

Pulmonary embolism major cause of cardiac arrest in those with psychiatric disorders

Results of a 5-year study in Japan suggest pulmonary embolism may be a major cause of sudden cardiac arrest among patients with psychiatric disorders.

News
December 14, 2021
1 min read
Save

Schizophrenia drug improves cognitive function in phase 2a trial

A single-arm, single-blind, phase 2a study of the neuromodulating drug RL-007, initiated by biopharmaceutical company atai Life Sciences, revealed its effectiveness in improving cognitive function and awareness in patients with schizophrenia.

News
December 13, 2021
1 min read
Save

Social fragmentation may increase risk for psychosis

Areas with high levels of social fragmentation had higher rates of psychosis, according to results of a systematic review published in Journal of Clinical Psychiatry.

News
December 13, 2021
2 min read
Save

Combination products containing opioid antagonists: What prescribers need to know

Combination products containing opioid antagonists: What prescribers need to know

FDA recently approved Lybalvi for the treatment of schizophrenia and for use in manic and mixed (depressive and manic) episodes of bipolar I disorder as an acute treatment, a maintenance treatment, and for use with valproate or lithium.

News
December 03, 2021
2 min read
Save

Pimavanserin may reduce negative symptoms of schizophrenia

A 26-week, randomized, double-blind, placebo-controlled phase 2 study showed pimavanserin reduced negative schizophrenia symptoms in stable patients.

View more